Find a Clinical Trial

A Phase II Trial of Dasatinib in Patients with Lung Adenocarcinoma with Acquired Resistance to Erlotinib or Gefitinib

[Protocol 06-143]

---

Full Title :

A PHASE 2 TRIAL OF DASATINIB IN PATIENTS WITH LUNG ADENOCARCINOMA RECEIVING ERLOTINIB WITH ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS (TKIS)

Purpose :

Erlotinib (Tarceva^®) and gefitinib (Iressa^®) are two targeted anticancer drugs used to treat lung cancer. However, lung cancer may become resistant to these drugs. The purpose of this study is to evaluate the safety and effectiveness of a drug called dasatinib (Sprycel^TM) in patients with lung adenocarcinoma that no longer responds to erlotinib or gefitinib.

Dasatinib is approved for treating certain types of leukemia. Laboratory studies have shown that it can kill cancer cells that appear to be similar to some types of lung cancer. Dasatinib is thought to cause cancer cells to die by inhibiting a protein called SRC. It is a pill that is taken by mouth twice a day.

Eligibility :

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

• Patients must have a confirmed diagnosis of lung adenocarcinoma that has continued to grow despite at least 6 months of treatment with erlotinib or gefitinib. Patients must have a biopsy at MSKCC of a site of progressive disease to be eligible for the protocol.
• At least 3 weeks must have passed since completion of any prior chemotherapy or radiation therapy and entry into the study.
• Patients must be age 18 or older.

For more information and to see if you are eligible for this study, please contact Dr. Vincent Miller at 212-639-7243.